|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3750 AUD | -1.32% |
|
+1.35% | -42.31% |
| 07-30 | Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy | MT |
| 07-21 | Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter | MT |
| Market Cap | 112M 79.36M 68.66M 64.12M 58.78M 111M 7.55B 751M 295M 3.79B 298M 291M 12.53B | P/E 2026 * |
-6.15x | P/E 2027 * | -4.41x |
|---|---|---|---|---|---|
| Enterprise Value | 118M 83.06M 71.86M 67.11M 61.52M 116M 7.9B 786M 309M 3.97B 312M 305M 13.11B | EV / Sales 2026 * |
15.1x | EV / Sales 2027 * | 11x |
| Free-Float |
62.79% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.32% | ||
| 1 week | +1.35% | ||
| Current month | +1.35% | ||
| 3 months | -25.00% | ||
| 6 months | -34.21% | ||
| Current year | -42.31% |
| 1 week | 0.36 |  | 0.38 |
| 1 month | 0.35 | | 0.39 |
| Current year | 0.35 | | 0.73 |
| 1 year | 0.35 | | 0.73 |
| 3 years | 0.28 | | 0.74 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 2/24/26 A | Expiration | Chief Executive Officer | 2,250,000 | 0.7781% | ||
| 10/14/25 A | Expiration | Chief Executive Officer | 745,962 | 0.3217% | ||
| 11/21/24 A | Buy | Director | 1,000,000 | 0.4313% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.32% | +1.35% | 0.00% | -46.43% | 79.31M | |
| -0.52% | +3.21% | +89.52% | +127.32% | 1,057B | |
| +0.88% | +1.13% | +49.56% | +49.69% | 625B | |
| +0.89% | -1.95% | +24.23% | +64.44% | 435B | |
| +0.71% | +3.87% | +49.07% | +37.85% | 363B | |
| +0.64% | -0.49% | +33.94% | +40.01% | 296B | |
| +0.39% | -5.83% | +8.92% | +7.85% | 249B | |
| +1.51% | +6.69% | +42.58% | +57.57% | 222B | |
| +3.92% | -0.46% | -5.56% | -52.32% | 209B | |
| +1.80% | +2.30% | +11.56% | +66.35% | 165B | |
| Average | +0.89% | +0.91% | +30.38% | +35.23% | 362.09B | |
| Weighted average by Cap. | +0.66% | +1.22% | +48.72% | +64.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.78M 5.5M 4.76M 4.44M 4.07M 7.66M 523M 52.03M 20.44M 263M 20.63M 20.18M 868M | 12.5M 8.83M 7.64M 7.13M 6.54M 12.31M 840M 83.58M 32.83M 422M 33.14M 32.42M 1.39B |
| Net income | -18.29M -12.93M -11.18M -10.44M -9.57M -18.02M -1.23B -122M -48.07M -617M -48.51M -47.46M -2.04B | -25.1M -17.74M -15.35M -14.33M -13.14M -24.73M -1.69B -168M -65.95M -847M -66.57M -65.12M -2.8B |
| Net Debt | 5.24M 3.7M 3.2M 2.99M 2.74M 5.16M 352M 35.01M 13.76M 177M 13.88M 13.58M 584M | 24.96M 17.64M 15.26M 14.25M 13.07M 24.59M 1.68B 167M 65.59M 843M 66.21M 64.77M 2.79B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/08/26 | A$0.3750 | -1.32% | 54,492 |
| 06/08/26 | A$0.3800 | +1.33% | 45,217 |
| 05/08/26 | A$0.3750 | 0.00% | 7,916 |
| 04/08/26 | A$0.3750 | -1.32% | 6,060 |
| 03/08/26 | A$0.3800 | +2.70% | 120,803 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
